Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs - supplementary material
dataset
posted on 2023-06-07, 08:51 authored by Mufiza Farid-Kapadia, Madelyn Barton, Zoe Bider-Canfield, Parneet K Cheema, Bishal Gyawali, Natalie M Nightingale, Lidija Latifovic, Henry J Conter
Supplementary Table 1: Tumor-Specific Trial Search Strategy
Supplementary Table 2: Tumor-Agnostic Trial Search Strategy
Exhibit 3: Tumor-agnostic trial characteristics
Supplementary Table 4: Tumor-agnostic cohort characteristics
Supplementary Table 5: Progression-free survival (PFS) and overall survival (OS) estimates from tumor-agnostic trials.
Supplementary Table 6: Tumor-specific trial characteristics
Supplementary Table 7: Tumor-specific cohort characteristics
Supplementary Table 8. Progression-free survival (PFS) and overall survival (OS) estimates from tumor-specific trials.
Supplementary Figure 1: Meta-analysis of BRAF inhibitors by trial type.
Supplementary Figure 2: Meta-analysis of BRAF/MEK inhibitors by trial type.
